773 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by Destination Wealth Management

Destination Wealth Management acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 773 shares of the company's stock, valued at approximately $320,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cranbrook Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 7.0% during the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after acquiring an additional 25 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after purchasing an additional 26 shares during the last quarter. Summit Trail Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after purchasing an additional 26 shares in the last quarter. First Horizon Advisors Inc. increased its stake in shares of IDEXX Laboratories by 4.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 704 shares of the company's stock valued at $356,000 after purchasing an additional 27 shares during the last quarter. Finally, Concurrent Investment Advisors LLC raised its holdings in shares of IDEXX Laboratories by 4.7% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 630 shares of the company's stock worth $318,000 after buying an additional 28 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Remove Ads

IDEXX Laboratories Trading Up 0.3 %

NASDAQ:IDXX traded up $1.09 during trading hours on Friday, hitting $430.12. 654,250 shares of the company were exchanged, compared to its average volume of 542,991. The stock has a market capitalization of $34.98 billion, a price-to-earnings ratio of 40.31, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $562.25. The company has a fifty day simple moving average of $437.37 and a 200 day simple moving average of $449.41. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent analyst reports. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Bank of America boosted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target for the company. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.